studies

Archimedes IndiGO End-Stage Renal Disease Tool Development and Validation

Archimedes IndiGO will be used to predict outcomes for Chronic Kidney Disease and provide an interface for patient management. The accuracy of outcomes prediction will be tested in this study.

Principal Investigator:

Stephen F. Derose, MD, MSHS

Funding Source:

Kaiser Foundation Health Plan, Inc.

Funding Years:

2013 - 2015

Assessing the Relationship between Parental Activation and Obesity-related Health Behaviors among Overweight and Obese Low-income Racial/Ethnic Minority Young Patients

The goal of this study is to determine the association between parental activation and obesity-related health behaviors in overweight/obese youth from low-income or racial/ethnic minority background.

Principal Investigator:

Corinna Koebnick, PhD, MSc

Funding Source:

Kaiser Permanente and Johns Hopkins Medicine Research Collaboration Committee

Funding Years:

2017 - 2018

Cholesterol-lowering medication as risk factors for amyotrophic lateral sclerosis

The primary objective of this study is to investigate whether the use of cholesterol-lowering medications increases the risk of developing ALS or influences the rate of disease progression among individuals who have ALS.

Principal Investigator:

Annette M. Langer-Gould, MD, PhD, MS

Funding Source:

Centers for Disease Control and Prevention (CDC)

Funding Years:

2012 - 2013

Do inpatient antimicrobial stewardship programs help us in the battle against antimicrobial resistance?

We propose to conduct a comprehensive analysis of the impact of ASPs on relevant clinical outcomes in a large integrated health care system. Specifically, we will evaluate the changes in consumption of targeted ASP drugs pre- and post-ASP and the changes in inpatient infection rates with clinically important drug-resistant organisms (DROs) pre- and post-ASP.

Principal Investigator:

Sara Yee Tartof, PhD, MPH

Funding Source:

National Institutes of Health (NIH)

Funding Years:

2017 - 2019

Identification of risk factors for resistant Pseudomonas aeruginosa infections with or without ESBL among hospitalized patients and developments and validation of a risk predictive tool

This study aims to develop a clinical risk prediction tool for antibiotic resistant Pseudomonas infections among inpatients.

Principal Investigator:

Sara Yee Tartof, PhD, MPH

Funding Source:

Merck & Co., Inc.

Funding Years:

2016 - 2019

Multiple sclerosis clinical care physician fellowship program

Training and mentoring of resident in treatment of multiple sclerosis.

Principal Investigator:

Annette M. Langer-Gould, MD, PhD, MS

Funding Source:

National Multiple Sclerosis Society (NMSS)

Funding Years:

2013 - 2014